Indirect effects of a 7 year PCV7/PCV13 mass vaccination program in children on the incidence of pneumonia among adults: A comparative study based on two Polish cities

Current Medical Research and Opinion

Volumn 32, Issue 3, 2016, Pages 397-403

  Patrzalek M ^a   Kotowska, M ^b   Gorynski P ^c   Albrecht, P ^b  

^a Nzoz Promed   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NATIONAL INSTITUTE OF HYGIENE   (Poland)

Author keywords

13 valent conjugate pneumococcal vaccine; Adults; Children; Heptavalent conjugate pneumococcal vaccine; Herd immunity; Pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; GROUPS BY AGE; HERD IMMUNITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; PNEUMONIA; RETROSPECTIVE STUDY; CITY; MIDDLE AGED; POLAND; VACCINATION;

ADULT; AGED; CITIES; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INCIDENCE; MASS VACCINATION; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA; POLAND; RETROSPECTIVE STUDIES; VACCINATION;

EID: 84959248883     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1119676     Document Type: Article

References (35)

1. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32
2. Farha T, Thomson AH. The burden of pneumonia in children in the developed world. Paediatr Respir Rev 2005;6:76-82
3. Varon E, et al. Centre National de Référence des Pneumocoques. Rapport d'activité2009-Epidémiologie 2008. http://cnr-pneumo.com/docs/rCNRP2009/CNRP2009.pdf [accessed 2015 August 10]
4. Foy HM, Cooney MK, Allan I, Kenny GE. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979;241:253-8
5. Murphy TF, Henderson FW, Clyde Jr WA, et al. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 1981;113:12-21
6. McConnochie KM, Hall CB, Barker WH. Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice. Am J Public Health 1988;78:34-9
7. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004;113:701-7
8. Korppi M, Heiskanen-Kosma T, Jalonen E, et al. Aetiology of communityacquired pneumonia in children treated in hospital. Eur J Pediatr 1993;152:24-30
9. Drummond P, Clark J, Wheeler J, et al. Community acquired pneumonia-A prospective UK study. Arch Dis Child 2000;83:408-12
10. Marston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-18
11. Black SB, Shinefield HR, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95
12. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-15
13. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 2007;369: 1179-86
14. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007;161:1162-8
15. Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 2008;26:5944-51
16. Durando P, Crovari P, Ansaldi F, et al. Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunization against Streptococcus pneumoniae: The five-year experience of Liguria Region, Italy. Vaccine 2009;27:3459-62
17. Pírez MC, Algorta G, Cedrés A, et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 2011;30:669-74
18. Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013;19:589-97
19. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009;4:CD004977
20. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010;29:607-12
21. Patrzałek M, Albrecht P, Sobczyński M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010;29:787-92
22. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Morb Mortal Wkly Rep 2005;54:893-7
23. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2010;2:e00309-10
24. Patrzałek M, Goryński P, Albrecht P. Indirect, population impact of universal PCV7 vaccination of children in 2+1 schedule on the incidence of pneumonia morbidity in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2012;31:3023-8
25. Käyhty H, A hman H, Eriksson K, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005;24:108-14
26. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre-and fullterm infants. Vaccine 2005;23:1703-8
27. Abramson JH. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiologic Perspectives & Innovations 2004;1:6. http://archive. biomedcentral.com//1742-5573/1/6. [accessed 2015 August 10]
28. Skoczyńska A, Sadowy E, Bojarska K, et al. The current status of invasive pneumococcal disease in Poland. Vaccine 2011;29:2199-205
29. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003;21:1815-25
30. Levine OS, O'Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet 2006;367:1880-2
31. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: A cross-sectional study. PLoS Med 2011;8:e1001017
32. Hak E, Grobbe DE, Sanders EA, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66:378-83
33. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-253
34. Grzesiowski P, Skoczynska A, Albrecht P, et al. Polish Pediatric IPD Group. Invasive pneumococcal disease in children up to 5 years of age in Poland. Eur J Clin Microbiol Infect Dis 2008;27:883-5
35. van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: A randomized controlled trial. JAMA 2009;302:159-67